Targeted Therapy and Immunotherapy in Melanoma

Jake Lazaroff; Diana Bolotin

doi:10.1016/j.det.2022.07.007

Targeted Therapy and Immunotherapy in Melanoma

Dermatol Clin. 2023 Jan;41(1):65-77. doi: 10.1016/j.det.2022.07.007. Epub 2022 Oct 28.

Authors

Jake Lazaroff¹, Diana Bolotin²

Affiliations

¹ Department of Medicine, Section of Dermatology, University of Chicago, The University of Chicago Medicine, 5841 S Maryland Avenue MC 5067, Chicago, IL 60637, USA. Electronic address: Jake.Lazaroff@uchospitals.edu.
² Department of Medicine, Section of Dermatology, University of Chicago, The University of Chicago Medicine, 5841 S Maryland Avenue MC 5067, Chicago, IL 60637, USA.

PMID: 36410984
DOI: 10.1016/j.det.2022.07.007

Abstract

While metastatic melanoma still carries significant mortality rates, the introduction of targeted therapy with BRAF/MEK inhibition and immunotherapy with PD-1, PD-L1, and CTLA-4 inhibitors has led to significant strides in outcomes and prognosis.

Keywords: Immunotherapy; Melanoma; Targeted; Therapy.

Publication types

Review

MeSH terms

Humans
Immunotherapy*
Melanoma* / drug therapy
Melanoma* / pathology
Molecular Targeted Therapy
Prognosis